Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8
Conditions
Brief summary
This clinical trial evaluates whether engineering gut microbiome using probiotics will alter the body's immune system to react to stage I-III breast or lung cancers that can be removed by surgery (operable). Having diverse species of bacteria inside the bowel may help improve the immune system, particularly the ability of the immune system to recognize cancer. Taking probiotics may change the diversity and make up of the bacteria in the bowels, and change how the immune system reacts to breast or lung cancer.
Detailed description
PRIMARY OBJECTIVES: I. To conduct a pilot study of probiotics prior to surgery in operable breast and lung cancer patients. II. To evaluate systemic and intratumoral immunomodulatory effects of probiotics in operable breast and lung cancer patients. OUTLINE: Patients undergo collection of blood samples at baseline and time of surgery, and collection of stool samples at baseline and after completion of probiotic regimen. Patients receive probiotics orally (PO) once on day 1, and then twice daily (BID) or three times daily (TID) for 2-4 weeks before standard of care surgery. Patients also undergo collection of tissue samples during standard of care surgery.
Interventions
PROCEDUREBiopsy
Undergo biopsy
PROCEDUREBiospecimen Collection
Undergo collection of blood, stool, and tissue samples
DRUGProbiotic
Given PO
PROCEDURETherapeutic Conventional Surgery
Undergo standard of care surgery
Sponsors
Mayo Clinic
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* \>= 18 years of age * Histologically confirmed adenocarcinoma of the breast operable stage I-III or histologically confirmed carcinoma of the lung operable stage I-III will be enrolled prior to their definitive surgery * Patients must have adequate organ function * Patients must be willing to provide tissue, blood and stool samples for the research study
Exclusion criteria
* Patients must not receive systemic neoadjuvant therapy * Patients must not have taken any probiotics in the past 30 days prior to the enrollment * Patients with autoimmune disease, immune deficiency such as human immunodeficiency virus (HIV), irritable bowel, known diverticulosis, and other serious gastrointestinal (GI) conditions at treating physician's discretion will be excluded
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Length and adherence of probiotics | Up to 4 weeks | Will be collected via study diaries. |
| Percentage of CD8+, CD4+, and T-reg cells | Baseline up to 4 weeks | — |
| Cytokine counts | Baseline up to 4 weeks | — |
Countries
United States
Outcome results
None listed